JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Search

Twist Bioscience Corp

Fechado

SetorSaúde

60.47 3.17

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.89

Máximo

60.75

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-8.39% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.1B

3.7B

Abertura anterior

57.3

Fecho anterior

60.47

Sentimento de Notícias

By Acuity

50%

50%

155 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de mai. de 2026, 23:47 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 de mai. de 2026, 22:35 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 de mai. de 2026, 23:32 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 de mai. de 2026, 23:20 UTC

Conversa de Mercado

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 de mai. de 2026, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 de mai. de 2026, 22:20 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 de mai. de 2026, 22:08 UTC

Ganhos

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 de mai. de 2026, 22:04 UTC

Ganhos

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 de mai. de 2026, 15:06 UTC

Ganhos

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-8.39% parte inferior

Previsão para 12 meses

Média 55.33 USD  -8.39%

Máximo 56 USD

Mínimo 55 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

155 / 347 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat